Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
31 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Nocturia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Nocturia - Pipeline Review, H2 2014', provides an overview of the Nocturia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nocturia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nocturia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nocturia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nocturia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nocturia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Nocturia Overview 5 Therapeutics Development 6 Pipeline Products for Nocturia - Overview 6 Pipeline Products for Nocturia - Comparative Analysis 7 Nocturia - Therapeutics under Development by Companies 8 Nocturia - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Nocturia - Products under Development by Companies 12 Nocturia - Companies Involved in Therapeutics Development 13 Allergan, Inc. 13 Drais Pharmaceuticals, Inc. 14 Ferring International Center S.A. 15 Sumitomo Dainippon Pharma Co., Ltd. 16 Vantia Therapeutics 17 Nocturia - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Nocturia - Dormant Projects 27 Nocturia - Product Development Milestones 28 Featured News & Press Releases 28 Feb 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial Of VA106483 For Nocturia 28 Jun 29, 2009: Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia 28 Mar 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 31 Disclaimer 31
List of Tables Number of Products under Development for Nocturia, H2 2014 6 Number of Products under Development for Nocturia - Comparative Analysis, H2 2014 7 Number of Products under Development by Companies, H2 2014 8 Comparative Analysis by Late Stage Development, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Nocturia - Pipeline by Allergan, Inc., H2 2014 13 Nocturia - Pipeline by Drais Pharmaceuticals, Inc., H2 2014 14 Nocturia - Pipeline by Ferring International Center S.A., H2 2014 15 Nocturia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 16 Nocturia - Pipeline by Vantia Therapeutics, H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Nocturia - Dormant Projects, H2 2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.